Eric Schadt, Acorda’s Cohen Join NY’s Life Science Disruptors Lineup

Over the past year, New York City has gone to great lengths to stamp itself as one of the nation’s big centers for genomics research. The New York Genome Center, for instance, came together because of a massive collaboration largest between Manhattan’s various medical institutions.

Now, we’re happy to say that Eric Schadt, one of the leaders in the genomics field and a director of the Icahn Institute for Genomics and Multiscale Biology, will be among the speakers on tap for Xconomy’s March 6 event, “New York’s Life Science Disruptors.”

Schadt will join a big-name list that also now includes Acorda Therapeutics (NASDAQ: [[ticker:ACOR]]) CEO Ron Cohen, who’ll help us kick off the festivities (and more) at the Apella event space at the Alexandria Center for Life Science on East 29th Street in Manhattan. It’ll be an interactive night of discussion and insight, as these local leaders envision how the New York area’s life sciences community can best seize on its current momentum to build a buzzing biotech cluster.

Here’s the full lineup of speakers you’ll see:

Ron Cohen: CEO, Acorda Therapeutics

Eric Schadt: Director, Icahn Institute for Genomics and Multiscale Biology

Marc Tessier-Lavigne: President of Rockefeller University, and a director of the New York Genome Center.

George Golumbeski: Senior vice president of business development at Celgene.

Francois Nader: President and CEO of NPS Pharmaceuticals, and the chairman of BioNJ.

Alex Denner: Founding Partner of Sarissa Capital Management.

We’ll post the full agenda soon. But you can grab tickets on our registration page now. The early bird discount ends next week. Looking forward to seeing you on March 6.

Author: Ben Fidler

Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.